Backed by 10+ years of research
Proprietary technology: 2 International Patents
Supported by Paris Saclay ecosystem
Built on CNRS-affiliated science
WHO WE ARE!
A cutting-edge technology company
e-miRgency is a cutting-edge technological startup with its roots firmly grounded in the Center for Nanosciences and Nanotechnologies Lab (C2N), a prestigious CNRS laboratory nestled in the thriving technological hub of Saclay, France. With over a decade of dedicated research and fruitful collaborations with esteemed scientific institutions, we've honed our expertise to deliver groundbreaking solutions.
Recognition and Support: Our commitment to innovation has not gone unnoticed. We are proud to have been handpicked, alongside other promising startups, by the Paris Saclay Cancer Cluster (PSCC) as trailblazing projects. This accolade grants us access to a wealth of expertise, comprehensive training, and the full spectrum of offerings from the PSCC, reinforcing our mission to revolutionize healthcare diagnostics
Our Technology
Revolutionizing diagnostics with our breakthrough technology: We've seamlessly integrated magnetic hyperthermia and electrochemical detection within a microfluidic chip. With two patents, registered know-how, and a wealth of scientific publications, we offer the future of precision, affordability, speed, and multiplexing capabilities in diagnostics—setting us apart from conventional methods like RT-PCR.
Magnetic hyperthermia
By leveraging the power of magnetic nanoparticles, our technology achieves what was once thought impossible. We capture elusive miRNAs even within complex samples, providing unparalleled specificity and sensitivity. Then, employing hyperthermia, we effortlessly release these miRNAs, unlocking a new realm of possibilities for precise diagnostics and early disease detection.
Microfluidic integration
Microfluidic technologies are at the heart of our innovation, enabling a transformative shift in diagnostics. With their precision and miniaturization, we drastically reduce the required sample volume, expand the scope of analyzed miRNAs, slash analysis time, minimize costs, and heighten sensitivity. This empowers us to provide faster, more comprehensive, and cost-effective diagnostic solutions that set new industry standards
Electrochemical detection
The incorporation of electrochemical detection into our system represents a groundbreaking advancement. This integration significantly lowers the limit of detection, making it possible to identify even trace amounts of miRNAs with exceptional accuracy. What's more, it simplifies the readout process, allowing for the use of straightforward electronic systems. This innovation not only enhances the precision of our technology but also streamlines its practical application, making it accessible and efficient for a wide range of users
Why Choose Us
In the battle against cancer, early detection is the key to saving lives. Yet, for far too long, the limitations of existing detection methods have left us with critical challenges. Traditional approaches are often invasive, costly, and can miss the mark when it comes to detecting cancer at its earliest and most treatable stages.
Why miRNAs Matter: This is where miRNAs step into the spotlight. MicroRNAs, abbreviated as miRNAs, are tiny but powerful molecules found within our cells. They hold immense promise as game-changing biomarkers for cancer detection and monitoring. MicroRNAs (miRNAs) are tiny molecules with enormous potential. As biomarkers, they offer a new frontier in cancer detection and follow-up, providing precise insights into early-stage disease and disease monitoring.
Our Mission: At e-miRgency, we're pioneers in harnessing miRNA technology to revolutionize cancer diagnostics and monitoring of early treatment response. Our solutions empower early and rapid intervention at the patient level and pave the way for precision medicine.
Scientific publications
M C Horny, M Lazerges J M Siaugue A Pallandre A M Haghiri Gosnet J Gamby DNA electrochemical hybridization detection in droplets using gold ultramicroelectrodes in a two-electrode configuration ECS Trans 72 31 2016 1 6
M ..−C Horny, M Lazerges J ..−M Siaugue A Pallandre D Rose, F Bedioui C Deslouis A ..−M Haghiri−Gosnet J Gamby Electrochemical DNA biosensors based on long−range electron transfer investigating the efficiency of a fluidic channel microelectrode compared to an ultramicroelectrode in a two−electrode setup Lab Chip 2016 16 4373 4381
Q Zhang, M Zhang, L Djeghlaf J Bataille, J Gamby A M Haghiri Gosnet A Pallandre § Logic digital fluidic in miniaturized functional devices Perspective to the next generation of microfluidic lab on chips Electrophoresis, 2017 38 7 1 24
M C Horny, V Dupuis, J M Siaugue and J Gamby Release and detection of microRNA by combining magnetic hyperthermia and electrochemistry modules on a microfluidic Sensor 2021 21 1 185 1 18
M C Horny, J Gamby V Dupuis, and J M Siaugue and Magnetic hyperthermia on γ Fe 2 O 3 @SiO 2 core shell nanoparticles for mi RNA 122 detection Nanomaterials 2021 11 1 149 1 25
M. C. Horny, F. Billon, A. Pailleret , C. Deslouis , V. Dupuis, M. lazerges , M. Siaugue , and J. Gamby . Amorphous carbon nitride microband integrated in a microfluidic device for DNA biosensors applications. J. Electroanal . Chem ., 2021 , 895 , 115395, 1 7.
P Gonzalez Losada, M Freisa C Poujouly and J Gamby An integrated multiple electrochemical miRNA sensing system embedded into a microfluidic Chip Biosensors 2022 12 45
C Poujouly P Gonzalez Losada, R Boukraa M Freisa J Le Gall, D Bouville C Deslouis and J Gamby Diffusion convection impedance for a micro band electrode under microfluidic conditions Electrochemistry Comm 2022 137 107262
C Poujouly J Le Gall, M Freisa D Kechkeche D Bouville J Khemir P Gonzalez Losada, and J Gamby Microfluidic chip for the electrochemical detection of microRNAs methylene blue increasing the specificity Frontiers in Chemistry 2022 10 868909
Patents
Patent: FR 3072097 2017 10 05 Method for detecting nucleic acid molecules by magnetic hyperthermia and kit therefor, Protected in France and USA
Patent: FR 2112764 2021 11 30 Binding of nucleic acids on platinum electrodes Protected in France and PCT application 052201
Our Team
In our dynamic team, we unite a diverse spectrum of expertise. From dedicated scientists and skilled engineers to seasoned professionals with extensive backgrounds in the pharmaceutical industry sales, marketing, and business development. Together, we form a cohesive force, ready to guide the company's journey from fundamental science through technology development and all the way to market access. Our collective knowledge and unwavering commitment fuel our mission to revolutionize diagnostics and make a lasting impact on healthcare.
The reference solution for the use of microRNAs in research, diagnosis and patient monitoring.
Contact Us
We will get back to you in less than 24 hours.